Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/134737
Campo DC Valoridioma
dc.contributor.authorDe Pablos Rodríguez, Pedroen_US
dc.contributor.authorClaps, Francescoen_US
dc.contributor.authorAcin, Ana Aldazen_US
dc.contributor.authorGomez-Ferrer, Alvaroen_US
dc.contributor.authorWong, Augustoen_US
dc.contributor.authorCatala, Juan Boronaten_US
dc.contributor.authorFons, Ana Calatravaen_US
dc.contributor.authorGarcia, Antonio Coyen_US
dc.contributor.authorBorja, Juan Casanova-Ramonen_US
dc.contributor.authorBackhaus, Miguel Ramirezen_US
dc.date.accessioned2024-11-18T18:39:08Z-
dc.date.available2024-11-18T18:39:08Z-
dc.date.issued2024en_US
dc.identifier.issn1078-1439en_US
dc.identifier.otherWoS-
dc.identifier.urihttp://hdl.handle.net/10553/134737-
dc.description.abstractIntroduction: Lymph node (LN) status is one of the main prognostic factors in localized prostate cancer (CaP) patients after surgery. Examining palpable lymph nodes with hematoxylin and eosin (HE) is the most common approach in clinical practice; however, immunohistochemistry (IHC) has been reported to increase the LN detection rate. We reviewed the oncological results of patients with LN metastasis detected by IHC. Methods: Retrospective study of CaP patients who underwent lymphadenectomy at the time of the prostatectomy. Extended lymphadenectomy was performed with complementary indocyanine green (ICG) guidance. Three groups were considered according to LN status. Definition of the pN+ group was made if LNs were detected by HE, occulted lymph node-positive (OLN+) was considered when >= 1 LN was identified with IHC and occulted lymph node-negative (OLN-) if no metastatic nodes were found. Oncological outcomes were reported regarding PSA kinetics, biochemical recurrence (BCR), need for secondary treatments and metastasis-free survival (MFS). Results: A total of 283 patients with a median follow-up of 69 months were included in the study. Immunohistochemical assessment revealed metastatic LNs in 8.9% of patients. The rate of locally advanced disease and positive surgical margins was higher in the OLN + and pN + groups vs the OLN - group (P < 0.05). At the end of follow-up, 19%, 44% and 52% of patients from the OLN -, OLN + and pN+ groups experienced BCR (P < 0.001), respectively. Additionally, 2.6%, 17% and 22% of patients developed metastatic progression from the OLN -, OLN + and pN+ group (P < 0.001), respectively. In the multivariate analysis, the OLN + group had a higher risk HR: 12 (95% CI, 2.4-56; P = 0.002) of metastatic progression in comparison with OLN - patients. This difference was not observed in the risk of Conclusion: Conventional HE histological analysis underdiagnosed nearly 10% of patients. IHC-detected patients were at higher risk of metastasis development than OLN - patients. This report highlights the importance of optimizing the anatomopathological analysis properly.en_US
dc.languageengen_US
dc.relation.ispartofUrologic Oncology: Seminars and Original Investigationsen_US
dc.sourceUrologic Oncology-Seminars And Original Investigations[ISSN 1078-1439],v. 42 (9), p. 288e1-288e6, (Septiembre 2024)en_US
dc.subject32 Ciencias médicasen_US
dc.subject320713 Oncologíaen_US
dc.subject321316 Urologíaen_US
dc.subject.otherRadical Prostatectomyen_US
dc.subject.otherDissectionen_US
dc.subject.otherMetastasesen_US
dc.subject.otherProstate Canceren_US
dc.subject.otherLymph Node Assessmenten_US
dc.subject.otherPathological Evaluationen_US
dc.subject.otherImmunohistochemistryen_US
dc.titleProstate cancer patients with lymphatic node involvement detected by immunohistochemistry. Is the effort worthwhile?en_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.urolonc.2024.05.003en_US
dc.identifier.isi001346263600001-
dc.identifier.eissn1873-2496-
dc.description.lastpage288e6en_US
dc.identifier.issue9-
dc.description.firstpage288e1en_US
dc.relation.volume42en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.contributor.daisngidNo ID-
dc.description.numberofpages6en_US
dc.utils.revisionen_US
dc.contributor.wosstandardWOS:de Pablos-Rodríguez, P-
dc.contributor.wosstandardWOS:Claps, F-
dc.contributor.wosstandardWOS:Acín, AA-
dc.contributor.wosstandardWOS:Gómez-Ferrer, A-
dc.contributor.wosstandardWOS:Wong, AGS-
dc.contributor.wosstandardWOS:Catalá, JB-
dc.contributor.wosstandardWOS:Fons, AC-
dc.contributor.wosstandardWOS:García, AC-
dc.contributor.wosstandardWOS:Borja, JCR-
dc.contributor.wosstandardWOS:Backhaus, MR-
dc.date.coverdateSeptiembre 2024en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.sjr0,867
dc.description.jcr2,7
dc.description.sjrqQ1
dc.description.jcrqQ2
item.grantfulltextopen-
item.fulltextCon texto completo-
crisitem.author.fullNameDe Pablos Rodríguez, Pedro-
Colección:Artículos
Adobe PDF (917,1 kB)
Vista resumida

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.